MannKind (MNKD) delivered strong financial results for the fourth quarter — noteworthy for the best-ever quarterly sales of the inhaled insulin Afrezza and the product’s first-ever gross profit.
This is news largely because the words “MannKind” and “strong financial results” have never appeared together in a sentence. In almost all respects, MannKind has been a raging, insulin-delivery dumpster fire, so give management credit for a quarter that hints at a turnaround. There’s still a long way to go.
About the Author Reprints
